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INTRODUCTION 
Glaucoma is a condition in which the pressure exerted by 
the liquid within the eyeball (the aqueous humor) is too 
great. The high pressure damages the optic nerve at the 
back of the eye. The damage interferes with the ability of 
the nerve to transmit visual images from the eye to the 
brain and thus can lead to blindness. Prostaglandins control 
the flow of the aqueous humor out of the eye.  Latanoprost, 
a derivative of the chemical, prostaglandin F2-alpha, is 
used for the treatment of glaucoma. 1-4 Latanoprost, by 
binding to a specific receptor for prostaglandin, increases 
the flow of aqueous humor out of the eye, thereby reducing 
the pressure within the eye and reducing the risk of nerve 
damage and blindness. When Latanoprost and Timolol (a 
different drug that also is used to treat glaucoma) are used 
in combination, there is a greater reduction in pressure 
than when either drug is used alone. Timolol blocks beta-
receptors that are found on the ciliary body. 5-7 This action 
reduces the amount of aqueous humour that is secreted into 
the eyeball by ciliary body. Timolol also blocks beta-
receptors found on the blood vessels that supply the ciliary 
body. This causes the blood vessels to constrict, and 
reduces the amount of watery fluid that filters out of the 
blood vessels to form aqueous humour. Timolol therefore 
works by reducing the inflow of aqueous humour into the 
eyeball, which decreases the pressure within the eye. It is 
used to treat conditions where there is raised pressure in 
the eye, such as glaucoma. 8-9  
The aim of this study was to develop a RP HPLC method 
for the quantitative simultaneous determination of 
Latanoprost, Timolol and Benzalkonium chloride (BAK). 
The method developed was validated as per ICH Q2 (R1).  
EXPERIMENTAL  
Chemicals and reagents 
HPLC grade acetonitrile, potassium dihydrogen 
orthophosphate were used to prepare the mobile phase and 
were purchased from Merck Specialities. The working 
standards of Latanoprost, Timolol and BAK were 
purchased from LG Promochem. Deionized and purified 
water using a Mili-Q system (Millipore) was used for the 
mobile phase and the standard solutions preparation. All 
experiment was performed using „A‟ class volumetric 
glassware. All other reagents were of analytical grade. 
Instrument and Chromatographic Conditions 
Shimadzu LC 2010 CHT HPLC was used for the 
chromatographic separation equipped with autosampler 
and Photo diode array (PDA) detector. The software used 
was LC Solution. The chromatographic separation of 
Latanoprost, Timolol and BAK was carried out using 
Inertsil C18 300 x 3.9 mm, 5µ reverse phase analytical 
column. Mobile phase consisted of Acetonitrile: Buffer 
(3.4 g potassium di hydrogen phosphate in 1000 ml WFI 
and pH adjusted to 2.8 with orthophosphoric acid) in the 
ratio 60: 40. The mobile phase was filtered by passing it 
through 0.45 µm filter and the filtrate is degassed by using 
bath sonicator. Mobile phase was used as diluent. Injection 
volume was 10 μL. Oven temp was set at 30oC. The 
mobile phase was pumped at 1 ml/min at room 
temperature. Detection was carried by using wavelength 
gradient given in Table 1. 
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Table 1: Wavelength Gradient 
Time (Min.)  0.01 5.00 5.01 12.00 15.00 
λ max 254 nm 254 nm 210 nm 210 nm Stop 
 
Method Development 
8-12
 
Different columns containing L1 and L7 stationary phase 
were tried for separation and resolution. Inertsil-3V 
column was found satisfactory over the other columns. The 
UV spectrum of Timolol, BAK and Latanoprost were 
scanned on photo diode array detector for selecting the 
optimum wavelength. Wavelength gradient was used in 
order to optimize the response of Timolol as its 
concentration was higher than Latanoprost in the sample. 
A typical HPLC chromatogram for simultaneous 
determination of latanoprost and timolol maleate from 
pharmaceutical formulation is shown in figure 1 and 2.  
Preparation of standard and test solution  
Prepare standard solution and test solution having 
concentration of Latanoprost (0.01 mg/ml), BAK (0.04 
mg/ml) and Timolol (1 mg/ml) dilute to the mark by 
diluent (mobile phase). 
RESULTS AND DISCUSSION 
Method Validation 
Specificity 
The test was carried out by injecting 10 µl standard 
solutions of Latanoprost (0.01 mg/ml), Timolol (1 mg/ml) 
and BAK (0.04 mg/ml) in five replicates. The RSD values 
for areas of Latanoprost, Timolol and BAK standard were 
found 0.09 %, 0.12%, 0.15 % respectively. Resolution, 
Theoretical plates and Tailing factor were determined. 
Results are shown in table 2.  
 
Table 2: System Suitability Parameters 
 
 
 
 
 
Linearity 
The linearity of an analytical procedure within a given 
range is its ability to obtain test results, which are directly 
proportional to the concentration of analyte in the standard. 
The range is derived from the linearity studies. A linearity 
standard solution was prepared at about 25%, 50%, 75%, 
100%, 125% and 150% of the standard solution 
concentration and then linearity correlation coefficient of 
Timolol, BAK and Latanoprost obtained from the graph 
obtained by plotting area count on Y axis  and 
concentration on X axis. Correlation coefficient of 
Timolol, BAK and Latanoprost are shown in table 3. 
Table 3: Correlation Coefficient 
 
Precision 
System precision 
The six injections of standard solutions were injected to the 
chromatographic system. The relative standard deviation for 
area and retention time of Timolol, BAK and Latanoprost 
peak was determined and shown in table 4.  
Method Precision 
Six sample of a single batch of Timolol, BAK and 
Latanoprost peak were analyzed by proposed method and 
their assay was calculated and results are shown in table 4. 
 
Table 4: System Precision and Method Precision 
 
 
 
 Resolution  Tailing factor  Theoretical plates  
Timolol   - 1.2 2803.45 
BAK 12.9 1.5 7364.09 
Latanoprost 7.486 1.066 11254.11 
Timolol BAK Latanoprost 
0.9995 0.9998 0.9994 
System Precision 
% RSD Timolol BAK Latanoprost 
AREA 0.12% 0.15 % 0.09 %, 
RT 0.08% 0.05% 0.06% 
Method Precision 
% RSD of assay 0.43 0.59 0.34 
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Accuracy (Recovery)  
The accuracy of an analytical procedure expresses the 
closeness of agreement between the value, which is 
accepted either as a conventional true value or an accepted 
reference value and the found value. Recovery samples 
were prepared in triplicate and injected each sample in 
duplicate to the chromatography system. Timolol, BAK 
and Latanoprost peak working standard was added with 
placebo and recovery solutions were prepared so that, the 
final concentration contains 50%, 100% and 150 % of the 
recovery levels of Timolol, BAK and Latanoprost and 
results are shown in table 5. 
 
Table 5: Accuracy (Recovery) 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
Limit of Detection and Quantification 
The limit of detection and Quantification were calculated as per formulas given below 
 
Where σ is standard deviation and S is the slope of the calibration curve. The LOD and LOQ values of Timolol, BAK and 
Latanoprost are shown in table 6.  
Table 6: LOD and LOQ 
 
 
 
 
 
Robustness 
The robustness of an analytical procedure is a measure of 
its capacity to remain unaffected by small, but deliberate 
variations in method parameters and provides an indication 
of its reliability during normal usage. 
The analysis was carried out used the method outlined in 
the method of analysis and by carried out the following 
alterations and results are shown in table 7 and 8. 
a) By changing the flow rate of the HPLC System by 0.1 
mL/min. 
b) By changing the column oven temperature by + 5°.
 
 
Analyte Conc. Added (ppm) RSD (%) Mean (%) Recovery 
Latanoprost 
5 0.502 100.33 
10 0.706 100.43 
15 0.436 100.31 
Timolol 
500 0.209 100.06 
1000 0.598 100.28 
1500 0.334 100.13 
BAK 
20 0.325 100.18 
40 0.666 100.01 
60 0.525 100.33 
 Timolol   BAK Latanoprost 
LOD (ppm) 0.4 0.6 0.2 
LOQ (ppm) 0.8  0.9 0.6 
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Table 7:  Robustness by changing flow rate 
 
 
 
 
 
 
 
 
Table 8:  Robustness by changing temperature 
 
 
 
 
 
 
 
 
 
Figure 1: Chromatogram of Latanoprost, Timolol and BAK in standard preparation 
 
Figure 2: Chromatogram of Latanoprost, Timolol and BAK in sample preparation 
At flow rate 1.1 ml/ min 
 Timolol   BAK Latanoprost 
% RSD 0.14 0.16 0.09 
Tailing factor 1.21 1.53 1.081 
Theoretical plates 2818.36 7357.13 11269.11 
At flow rate 0.9 ml/ min 
% RSD 0.15 0.17 0.12 
Tailing factor 1.31 1.64 1.18 
Theoretical plates 2829.31 7321.01 11245.18 
At Temp 25oC 
 Timolol   BAK Latanoprost 
% RSD 0.16 0.20 0.09 
Tailing factor 1.34 1.67 1.10 
Theoretical plates 2865.29 7312.16 11231.09 
At Temp 35oC 
% RSD 0.21 0.39 0.24 
Tailing factor 1.12 1.87 1.29 
Theoretical plates 2953.63 7419.26 11210.49 
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CONCLUSION  
The present study shows that the method developed for the 
determination of Timolol, BAK and Latanoprost was 
specific, linear, accurate, precise and robust. Wavelength 
gradient was used in order to optimize the response of 
Timolol as its concentration was higher than Latanoprost 
in the sample. The method clearly shows that all the peaks 
had tailing factor less than 2. The RSD for areas and 
theoretical plates (> 2500) was also found to be 
satisfactory. Validation parameters were performed 
according to ICH Q2 (R1) guidelines. The recoveries 
achieved were highly significant in the developed method. 
Hence it can be concluded that the method developed can 
be effectively used in the industries as well as research 
purposes.  
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